Form 4: Immunovant's Chief Medical Officer, Michael Geffner, Reports Acquisition and Disposal of Shares

Michael Geffner, Chief Medical Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On April 2, 2024, Michael Geffner, the Chief Medical Officer of Immunovant, Inc., reported transactions involving Immunovant's common stock and derivative securities.
• Geffner acquired 54,978 restricted stock units (RSUs) and disposed of 144,877 shares of common stock.
• He also acquired options to purchase 68,723 shares of common stock at an exercise price of $30.78.
• The RSUs and stock options vest over time, contingent upon Geffner's continued service to Immunovant.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to investors regarding the actions of key personnel.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates